Evidence map›Paper›PMID 40197022›Full record

ArticleJournal of proteome research2025

MSIght: A Modular Platform for Improved Confidence in Global, Untargeted Mass Spectrometry Imaging Annotation.

Lauren Fields, Hannah N Miles, Alexis E Adrian, Elliot Patrenets, William A Ricke, Lingjun Li

Abstract read
In one paragraph

Article in Journal of proteome research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Lauren FieldsDepartment of Chemistry, University of Wisconsin-Madison, 1101 University Avenue, Madison, Wisconsin 53706, United States.
Hannah N MilesSchool of Pharmacy, University of Wisconsin-Madison, 777 Highland Avenue, Madison, Wisconsin 53705, United States.
Alexis E AdrianDepartment of Urology, George M. O'Brien Center of Research Excellence, University of Wisconsin-Madison, 1111 Highland Avenue, Madison, Wisconsin 53705, United States.ORCID 0000-0002-8936-5991
Elliot PatrenetsDepartment of Urology, George M. O'Brien Center of Research Excellence, University of Wisconsin-Madison, 1111 Highland Avenue, Madison, Wisconsin 53705, United States.
William A RickeDepartment of Urology, George M. O'Brien Center of Research Excellence, University of Wisconsin-Madison, 1111 Highland Avenue, Madison, Wisconsin 53705, United States.
Lingjun LiDepartment of Chemistry, University of Wisconsin-Madison, 1101 University Avenue, Madison, Wisconsin 53706, United States.ORCID 0000-0003-0056-3869

Funding

UW COMPREHENSIVE CANCER CENTER SUPPORTP30CA014520 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI Justine Yang Bruce · 1985 to 2026
$142.6M
Role of Beta-Catenin in Urinary DysfunctionU54DK104310 · NIDDK · UNIVERSITY OF WISCONSIN-MADISON · PI RICKE, WILLIAM A · 2014 to 2023
$12.8M
Chemistry-Biology Interface Training ProgramT32GM008505 · NIGMS · UNIVERSITY OF WISCONSIN-MADISON · PI BLACKWELL, HELEN E. · 1993 to 2023
$9.8M
Mass Spectrometric Studies of Neuropeptides in FeedingR01DK071801 · NIDDK · UNIVERSITY OF WISCONSIN-MADISON · PI LINGJUN LI · 2006 to 2026
$6.7M
Creating a region- specific biomolecular atlas of the brain of Alzheimer’s diseaseR01AG078794 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI LINGJUN LI, Luigi Puglielli · 2022 to 2026
$3.7M
Graduate Training in Molecular and Cellular PharmacologyT32GM141013 · NIGMS · UNIVERSITY OF WISCONSIN-MADISON · PI Anjon Audhya, Aaron Matthew LeBeau · 2021 to 2026
$3.2M
Elucidating hallmarks of aging in the development of lower urinary tract dysfunction (LUTD)R01DK131175 · NIDDK · UNIVERSITY OF WISCONSIN-MADISON · PI RICKE, WILLIAM A · 2021 to 2024
$2.3M
DiLeu-enabled multiplexed quantitation for biomarker discovery and validation in Alzheimer’s diseaseR01AG052324 · NIA · UNIVERSITY OF WISCONSIN-MADISON · PI LINGJUN LI · 2023 to 2026
$2.3M
Acquisition of a High-Field Dual Source FTICR-MS for Pharmaceutical ResearchS10RR029531 · NCRR · UNIVERSITY OF WISCONSIN-MADISON · PI LI, LINGJUN · 2011 to 2011
$2.1M
Estrogen pathways in the development of prostatic fibrosis and lower urinary tract dysfunctionR01DK127081 · NIDDK · UNIVERSITY OF WISCONSIN-MADISON · PI RICKE, WILLIAM A · 2021 to 2024
$2.0M
Chemistry-Biology Interface Training ProgramT32GM152341 · NIGMS · UNIVERSITY OF WISCONSIN-MADISON · PI Helen E. Blackwell · 2024 to 2026
$1.6M
Acquisition of a Dual-Source, High-Performance, Ion Mobility, Quadrupole Time-of-Flight Mass Spectrometry System for Biomedical Research at UW-MadisonS10OD028473 · OD · UNIVERSITY OF WISCONSIN-MADISON · PI LI, LINGJUN · 2021 to 2021
$1.3M
NCI NIH HHS P30 CA014520NCRR NIH HHS S10 RR029531NIA NIH HHS R01 AG052324NIA NIH HHS R01 AG078794NIDDK NIH HHS F31 DK135376NIDDK NIH HHS F31 DK136335NIDDK NIH HHS R01 DK071801NIDDK NIH HHS R01 DK127081NIDDK NIH HHS R01 DK131175NIDDK NIH HHS U54 DK104310NIGMS NIH HHS F31 GM156104NIGMS NIH HHS T32 GM008505NIGMS NIH HHS T32 GM141013NIGMS NIH HHS T32 GM152341NIH HHS S10 OD025084NIH HHS S10 OD028473
6 · The paper itself

Abstract

Mass spectrometry imaging (MSI) has gained popularity in clinical analyses due to its high sensitivity, specificity, and throughput. However, global profiling experiments are often still restricted to LC-MS/MS analyses that lack spatial localization due to low-throughput methods for on-tissue peptide identification and confirmation. Additionally, the integration of parallel LC-MS/MS peptide confirmation, as well as histological stains for accurate mapping of identifications, presents a large bottleneck for data analysis, limiting throughput for untargeted profiling experiments. Here, we present a novel platform, termed MSIght, which automates the integration of these multiple modalities into an accessible and modular platform. Histological stains of tissue sections are coregistered to their respective MSI data sets to improve spatial localization and resolution of identified peptides. MS/MS peptide identifications via untargeted LC-MS/MS are used to confirm putative MSI identifications, thus generating MS images with greater confidence in a high-throughput, global manner. This platform has the potential to enable large-scale clinical cohorts to utilize MSI in the future for global proteomic profiling that uncovers novel biomarkers in a spatially resolved manner, thus widely expanding the utility of MSI in clinical discovery.

Indexed as

ProteomicsAnimalsChromatography, LiquidHumansMicePeptidesTandem Mass SpectrometryPeptideshistologyimaging softwareMALDImass spectrometry imagingmultimodal imagingPythonspatial omics

Identifiers

PMID40197022
PMCPMC12097482

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.